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TABLE 1 Baseline Characteristics, Time Delays, and Outcomes
Baseline clinical characteristics
Female 37 (44)
Anterior stroke 82 (97)
Age, yrs 64.8  13.8
Diabetes mellitus 25 (30)
History of hypertension 63 (75)
Clinical evidence of atherosclerosis 37 (44)
Atrial ﬁbrillation (any type, any time) 34 (40)
History of stroke or TIA 9 (11)
Admission NIHSS 18.0  4.1 (median 18, range 6–27)
Time delays: median values, min (IQR: 25–75)
Stroke onset to CT 90 (55–145)
CT to sheath insertion 64 (24–89)
Sheath insertion to recanalization 53 (41–70)
Stroke onset to sheath insertion 165 (95–260)
Stroke onset to recanalization 236 (202–342)
Procedural data
Intubation/general anesthesia use 24 (29)
Heparin dose, units 3,570  3,800 (median 2500)
Angiographic and clinical outcomes
Recanalization rate (TICI 2a/2b/3 ﬂow) 62 (74)
Good neurological outcome at 90 days (mRS #2) 35 (42)
90-day mRS among early presenters
(stroke onset to sheath insertion time <3 h)
3.15  2.20 (median 2)*
90-day mRS among late presenters
(stroke onset to sheath insertion time >3 h)
3.81  2.11 (median 4)*
90-day mortality 27 (32)
Symptomatic intracranial hemorrhage at 7 days (%) 12 (14)
Values are n (%) or mean  SD, unless otherwise noted. *p ¼ 0.160.
CT ¼ computed tomography; IQR ¼ interquartile range; mRS ¼ modiﬁed Rankin scale; NIHSS ¼ National
Institutes of Health Stroke Score; TIA ¼ transient ischemic attack; TICI ¼ Thrombolysis In Cerebral Infarction.
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488class IA indication). In contrast, interventional car-
diology services for acute myocardial infarction are
available on a 24/7 basis in almost all European and
North American countries, and are becoming more
available on other continents. Thus, in places where
neuroradiology services are not available, the in-
volvement of interventional cardiologists may be a
reasonable option.
Direct mechanical thrombectomy performed by a
cardiologist may be considered a treatment option for
acute stroke in centers where no neurointerventional
services exist. Cardiology centers are able to achieve
short CT to catheter laboratory times due to their
experience in primary angioplasty for acute myocar-
dial infarction. Outcomes are comparable to endo-
vascular interventions performed in neuroradiology
centers.*Petr Widimsky, MD, DrSc
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204–7.Net Clinical Beneﬁt for
Oral Anticoagulation,
Aspirin, or No Therapy
in Nonvalvular Atrial
Fibrillation Patients With
1 Additional Risk Factor of
the CHA2DS2-VASc Score
(Beyond Sex)Whether to anticoagulate patients with atrial
ﬁbrillation (AF) and 1 stroke risk factor (i.e., CHA2DS2-
VASc [congestive heart failure, hypertension, age
FIGURE 1 Net Clinical Beneﬁt for Anticoagulation, Aspirin, or
No Therapy
No treatment
–1.84
0.55
0.59
–4 –2 0
Net Clinical Benefit
2 4
2.22 3.85
1.68 2.81
–0.54 0.75
No treatment
Aspirin Warfarin
Warfarin
Aspirin
Net clinical beneﬁt analyses for 1 year of follow-up, for aspirin
versus no treatment, warfarin versus no treatment, and for
warfarin versus aspirin.
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489>75 years, diabetes mellitus, stroke, vascular disease,
age 65–75 years, and female sex] score ¼ 1 in men,
or 2 in women) is controversial, but many studies
report ischemic stroke rates of >1.5% per year, even
with 1 stroke risk factor (1). We estimated the net
clinical beneﬁt (NCB) of aspirin or warfarin compared
with no antithrombotic therapy among such patients
on the basis of a nationwide Danish cohort, with
incident AF diagnosed between 1998 and 2012 (2).
Men with a CHA2DS2-VASc score s 1 and women with
score s 2 at the date of discharge after diagnosis
were excluded, as were patients who initiated non-
vitamin K antagonist (VKA) oral anticoagulants
(OACs), phenprocoumon, or who had warfarin or
aspirin prescriptions between 4 and 12 months
and before the date of AF diagnosis. Others were
stratiﬁed according to: 1) no treatment, if there was
no prescription for warfarin or aspirin within 1 year;
2) aspirin; or 3) warfarin prescriptions within 4
months.
Endpoint rates were calculated as events per 100
person-years. NCB was calculated for aspirin or
warfarin versus no treatment, and for aspirin versus
warfarin under intention-to-treat as a weighted sum
of rate differences DR ¼ Ratenot treated – Ratetreated:
NCB ¼ w1  DRischemic stroke þ w2  DRICH þ w3 
DRmajor bleeding þ w4  DRMI. When contrasting
aspirin and warfarin, the rate difference was given
as DR ¼ Rateaspirin – Ratewarfarin. Positive NCB
favored treatment (i.e., warfarin compared with
aspirin, or no treatment, respectively). Weights in
hazard ratios (HRs) were estimated from the entire
Danish AF cohort by Cox proportional hazards
models (3), on the basis of 1-year follow-up. NCB
with 95% conﬁdence intervals (CIs) were calculated
from rate differences and SEs using Poisson
regression.
NCBs for 1 follow-up are presented in Figure 1, on the
basis of weights: w1 ¼ 1, w2 ¼ 2.44, w3 ¼ 0.67, and
w4 ¼ 0.86. NCBs were positive for warfarin versus no
treatment (HR: 1.68; 95% CI: 0.55 to 2.81) and for
warfarin versus aspirin (HR: 2.22; 95% CI: 0.59 to 3.85).
The NCB for aspirin versus no treatment was negative
(HR: –0.54; 95% CI: –1.84 to 0.75).
This analysis supports a positive advantage for
stroke prevention with OACs compared with no
therapy or with aspirin among patients with AF who
have a single stroke risk factor other than a sex factor
(i.e., CHA2DS2-VASc score ¼ 1 in men or 2 in women).
The analysis by Friberg et al. (4) excluded patients
who received OACs during follow-up, which in-
troduced bias away from the null hypothesis that
patients with 1 additional risk factor beneﬁt from
OAC treatment.Ischemic stroke rates among such AF patients have
varied in reports from different cohorts, reﬂecting
the populations and settings from which the data are
derived (1,5). However, clinical risk status changes
over time, and hospitalized AF patients face greater
mortality and morbidity, whereas OAC reduces stroke
and all-cause mortality compared with placebo
and/or control drugs. Finally, NCB may be greater
with the non-VKA OACs than warfarin, because of
their better efﬁcacy and safety compared with the
VKAs in clinical trials.
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Late Cerebral Events After
Carotid Artery StentingWe read with great interest the recent paper by Gen-
sicke et al. (1), which reported a 3-fold increased risk of
recurrence of stroke or transient ischemic attack at 6
months in symptomatic patients treated with carotid
artery stenting (CAS) and who showed new silent
ischemic cerebral lesions on diffusion-weighted mag-
netic resonance imaging after the endovascular pro-
cedure. This observation did not apply to patients
treated with carotid endoatherectomy (CEA). The
investigators discussed the possible role of vulnerable
plaques and the potential beneﬁts of longer and more
aggressive antiplatelet therapy. The study provided
highly valuable new scientiﬁc evidence that might
improve the current clinical outcomes of CAS and ge-
nerated a hypothesis that deserves intensive in-
vestigation. However, the previously published ICSS
(International Carotid Stenting Study) data provided
little information on the kind of stent that was used
(2). With cerebral protection, plaque coverage is acritical issue for CAS success; although CEA could
remove almost the entire plaque, carotid stents have a
free area between the struts where plaque prolapse
could happen, with a risk of late embolization (3). It is
well known that the free area surface varies according
to stent design, with signiﬁcant differences between
open- and closed-cell stents; the latter has better pla-
que coverage and a lower incidence of plaque prolapse
(4). Since the ICSS study was performed, new mesh-
covered stents with a small, free-cell area have
become available, which potentially could reduce late
embolization from the stent-covered plaque. A more
aggressive medical therapy in this subset of patients is
advisable, but carotid stent characteristics should be
taken into account when considering the global risk of
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Cerebral Events After Carotid Artery StentingDrs. Pacchioni, Ribichini, and Reimers raise an
important issue about the effects of stent design on
outcomes after carotid artery stenting. The stent
design used was reported for 119 of 124 patients
who underwent stenting for symptomatic carotid
stenosis in the ICSS-MRI (International Carotid
Stenting Study-Magnetic Resonance Imaging) sub-
study; 74 patients (62%) received an open-cell stent
